Safety considerations in somatic gene therapy of human disease with retrovirus vectors.
Safety considerations in somatic gene therapy of human disease with retrovirus vectors.
复制标题
DOI：
10.1089/hum.1990.1.2-111
复制
发表时间：
1990
影响因子：
4.2
通讯作者：
H. Temin
中科院分区：
文献类型：
--
作者：
H. Temin
利用逆转录病毒载体对人类疾病进行体细胞基因治疗是一项具有潜在重要医学价值的新技术。虽然它涉及重组DNA技术和改良的逆转录病毒，但适当设计载体和递送系统可以消除大多数潜在的可预见风险。此外，即使这种治疗存在非治疗性生物效应的可能性很小，也不太可能是有害的。因此，一旦构建和使用非常安全的逆转录病毒载体辅助细胞系统，安全性考虑不应阻碍逆转录病毒载体的进一步人体试验。
Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Furthermore, even in the very remote possibility that there is a nontherapeutic biological effect of the treatment, it is unlikely to be a harmful one. Thus, once very safe retrovirus vector-helper cell systems are constructed and in use, safety considerations should not hold up further human trials of retrovirus vectors.